TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04578210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T memory cells and NK cells
Description: Single infusion of NK or memory T cells from a healthy donor recovered from COVID-19 (dose escalation).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T memory cells and NK cells
Description: Single infusion of NK or memory T cells from a healthy donor recovered from COVID-19 (dose escalation).
Study: NCT02101437

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: miRNA within 24hr
Description: miRNA within 24hr

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: miRNA within 24hr
Description: miRNA within 24hr

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: miRNA within 24hr
Description: miRNA within 24hr

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: miRNA within 24hr
Description: miRNA within 24hr

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: miRNA after 1 week
Description: miRNA after 1 week

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: miRNA after 1 week
Description: miRNA after 1 week

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: miRNA after 1 week
Description: miRNA after 1 week

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: miRNA after 1 week
Description: miRNA after 1 week

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: miRNA after 1 month
Description: miRNA after 1 month

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: miRNA after 1 month
Description: miRNA after 1 month
Study: NCT00393367

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone, prednisone, or methylprednisolone
Description: All patients are given 2mg/kg of systemic corticosteroids (max 60mg). Patients who can tolerate pills are given oral prednisone, those who cannot are given oral prednisolone, and those who cannot tolerate oral medications are given IV methylprednisolone.
Study: NCT01816763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NRS pain one week
Description: Eligible patients will be randomly assigned to complete a patient-reported 'NRS one week' on a tablet prior to making contact with a nursing staff vital signs screener.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEG
Description: Eligible patients will be assigned to complete a patient-reported enhanced pain screening with the PEG on a tablet prior to making contact with a nursing staff vital signs screener.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVPRS
Description: Eligible patients will be randomly assigned to complete a patient-reported 'DVPRS' on a tablet prior to making contact with a nursing staff vital signs screener.
Study: NCT00393367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol, ipratropium bromide
Description: While guardians are approached for possible participation, patients are given a single nebulized dose of albuterol sulfate (5mg/mL) mixed with ipratropium bromide (500mcg/2.5mL). Patients who weigh 10-20kg receive 3.75mg of albuterol. Patients over 20kg receive 5mg of albuterol. All patients receive 500mcg of ipratropium bromide. Albuterol sulfate and ipratropium bromide are delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
Study: NCT02101437

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: miRNA after 1 month
Description: miRNA after 1 month

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: miRNA after 1 month
Description: miRNA after 1 month
Study: NCT02993237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV/COBI FDC placebo tablet
Description: Participants will receive 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV/COBI FDC placebo tablet
Description: Participants will receive 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF FDC placebo tablets
Description: Participants will receive 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF FDC placebo tablets
Description: Participants will receive 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC.
Study: NCT02065778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell transplantation
Description: bone marrow derived mononuclear cells are administered intrathecally in chronic stroke patients
Study: NCT04057170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: accelerated protocol and mulligan method
Description: manual therapy technic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: accelerated protocol and mulligan method
Description: manual therapy technic
Study: NCT03018015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg oral powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg soft capsule
Study: NCT02528344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: All participants will undergo high intensity interval training 3x/week for 10-12 weeks. Intense exercise will be interspersed with appropriate rest periods of low intensity exercise
Study: NCT02687308

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1 Retrograde radical prostatectomy RRP
Description: This open surgical technique described by Patrick Walsh involves prostatic dissection made from prostatic apex to the bladder neck, so the retrograde direction, the posterior layer of Denonvilliers' fascia is always included with the specimen, and urethrovesical anastomosis usually performed with multifilament interrupted suture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2 Anterograde radical prostatectomy RRP2A
Description: This open surgical techniques performing radical retropubic prostatectomy using the same technique of minimally invasive surgery, antegrade way, from bladder neck to the apex, with careful bladder neck dissection and preservation, incremental or not careful nervesparing procedures and urethrovesical anastomosis performed by monofilament running suture, described by the Pasadena consensus for the procedure assisted by robot.
Study: NCT04246554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Oral ketorolac for pain control following ACL reconstruction surgery
Study: NCT00393367

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol, ipratropium bromide
Description: While guardians are approached for possible participation, patients are given a single nebulized dose of albuterol sulfate (5mg/mL) mixed with ipratropium bromide (500mcg/2.5mL). Patients who weigh 10-20kg receive 3.75mg of albuterol. Patients over 20kg receive 5mg of albuterol. All patients receive 500mcg of ipratropium bromide. Albuterol sulfate and ipratropium bromide are delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Description: 500 mcg/2.5mL. All patients receive a final dose of ipratropium bromide after the intervention or placebo. The ipratropium bromide is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM) with an oxygen flow rate of 8L/minute via a tight-fitting face mask.
Study: NCT04246554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone-Acetaminophen
Description: Oral oxycodone-acetaminophen for post-operative pain control
Study: NCT01258920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Description: Paliperidone palmitate will be administered im as an initial loading dose of 150 mg eq. on Day 1 and 100 mg eq. 1 week later in the deltoid muscle, and will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 for a total of 11 injections.
Study: NCT04574999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estriol
Description: Gel for vaginal application

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gel for vaginal application
Study: NCT03343821

Intervention type: OTHER
Intervention: Balance and daily life questionnaire
Description: Patients complete questionnaire
Study: NCT04746326

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Failure conservative treatment
Description: Surgery was performed in patients who failed conservative treatment.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: Surgery was performed in patients who had generalized peritonitis and perforation.
Study: NCT00393367

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ipratropium bromide
Description: 500 mcg/2.5mL. All patients receive a final dose of ipratropium bromide after the intervention or placebo. The ipratropium bromide is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM) with an oxygen flow rate of 8L/minute via a tight-fitting face mask.
Study: NCT02320409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfatinib
Description: 250mg Sulfatinib ,single dose,oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfatinib
Description: 250mg Sulfatinib ,single dose,oral
Study: NCT02456558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous deferiprone
Description: In Cohort 1, the subjects who were randomized to get active product will receive deferiprone at a dose of 1.5 g per infusion, and if there are no significant safety concerns, the subjects in Cohort 2 who were randomized to get active product will receive it a a dose of 2 g per infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous deferiprone
Description: In Cohort 1, the subjects who were randomized to get active product will receive deferiprone at a dose of 1.5 g per infusion, and if there are no significant safety concerns, the subjects in Cohort 2 who were randomized to get active product will receive it a a dose of 2 g per infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In both cohorts, the subjects who were randomized to get placebo will receive an infusion of placebo solution that is equal in volume to that of the active product.
Study: NCT00627146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChAgly CD3
Description: 6 days treatment 8mg/d intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 days
Study: NCT01908400

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Intravenous transfer of BMMNC
Description: Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
Study: NCT00480987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 30 mg/m\^2 IV days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 IV days 2-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 500 mg/m\^2 by IV continuous infusion days 2-6
Study: NCT01432951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzastaurin
Description: Administered orally
Study: NCT01145638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iron isomaltoside 1000
Description: intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iron sulphate
Description: oral, 200 mg per day (100 mg bid),12 weeks
Study: NCT02519855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX™
Description: A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (concomitant) or at Week 4 (nonconcomitant)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX™
Description: A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (concomitant) or at Week 4 (nonconcomitant)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo to ZOSTAVAX™
Description: A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (nonconcomitant) or at Week 4 (concomitant)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo to ZOSTAVAX™
Description: A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (nonconcomitant) or at Week 4 (concomitant)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: A single open-label administration of 0.5 mL intramuscular injection on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: A single open-label administration of 0.5 mL intramuscular injection on Day 1
Study: NCT01840644

Intervention type: OTHER
Intervention: Walking on treadmill, different velocities and incline
Description: Walking on treadmill twice, with one week interval in each session the child will walk in different velocities and incline
Study: NCT02907892

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glove change
Description: Intra-operative changing of sterile surgical gloves immediately prior to abdominal closure during cesarean section
Study: NCT02910128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: chiquichefs
Description: A project based learning using healthy trough cooking as the core of the curriculum, so children learn the academic content through cooking workshop of mediterranean diet in their school.
Study: NCT00507728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Counseling
Description: Counseling over 8 months and telephone support calls.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: Counseling over 8 months and telephone support calls.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Counseling
Description: Counseling over 8 months and telephone support calls.
Study: NCT04746326

Intervention type: OTHER
Group type: OTHER
Intervention: Conservative treatment
Description: Conservative treatment was performed in patients who had no generalized peritonitis and perforation.
Study: NCT03685448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: The 20 mg cabozantinib drug product is a film-coated, white, round, immediate-release tablet. Cabozantinib should not be stored above 25°C (77°F).
Study: NCT04531462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02673047

Intervention type: BIOLOGICAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A (Botox®) injection as prescribed as standard of care in clinical practice.
Study: NCT04590742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melatonin 6mg
Description: 6 weeks of melatonin (6mg) given to patient
Study: NCT04768933

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Toddler Milk
Description: At least three 130 mL servings daily of study formula are recommended for a total daily intake of 390 mL. Study participants will continue this feeding regimen Days 4 to 28 (approximately 4 weeks).
Study: NCT02018107

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: N-13 ammonia or F-18 fluorodeoxyglucose
Description: PET tracer

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET scan
Description: PET scan
Study: NCT02043730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel and Gemcitabine
Description: Chemotherapy will consist of nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.
Study: NCT04285437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: infant massage
Description: Mother will be trained how to massage their babies by International Association of Infant Massage (IAIM) Certified Infant Massage Instructor, and then their babies will be massaged by themselves during the first 2 months after birth.
Study: NCT02025452

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rapid diagnostic
Description: Specimens from rectal mucosa will be obtained using flocked swabs at enrolment. Those in 'rapid diagnostic' groups will have them tested using multiplex PCR the day of enrolment and participants with treatable pathogens will have antimicrobials provided. Those in 'delayed diagnostic' groups will have the swabs batched at tested at the conclusion of the study, being treated as per standard of care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rapid diagnostic
Description: Specimens from rectal mucosa will be obtained using flocked swabs at enrolment. Those in 'rapid diagnostic' groups will have them tested using multiplex PCR the day of enrolment and participants with treatable pathogens will have antimicrobials provided. Those in 'delayed diagnostic' groups will have the swabs batched at tested at the conclusion of the study, being treated as per standard of care.
Study: NCT04339868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: Terlipressin (20-100 mcg/hr) plus norepinephrine and/or epinephrine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl plus norepinephrine and/or epinephrine
Study: NCT03088501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive voice response system
Description: IVR allows the pregnant women, their family members to interact with a computer system using a telephone.Through IVR, women receive a 2-3 minute call that reminds them of lab test, their next follow-up visit and also provides information on child care attendance, breastfeeding, introduction of solid foods, motor development, and sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother and baby affairs workshop
Description: Mother and baby affairs workshop will involve antenatal workshop and counseling for parents. The intervention will involve brief talk by health professionals, quiz activities, role-plays on personal hygiene, nutritional food, institutional delivery, precautions at the time of delivery, caring for the baby, feeding of colostrum, homemade baby food, immunization, and family planning measures.
Study: NCT02718820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2; q21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg, q21
Study: NCT00648986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazorac
Description: All patients were to apply topical tazarotene (Tazorac) twice daily to all affected fingernails for 24 weeks.
Study: NCT02025452

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Lactobacillus reuteri suspended in vegetable oil, 5 drops/day (1 x 10e8 CFU) x 2 months
Study: NCT04590742

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient given 6 weeks of placebo tablet
Study: NCT04197687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-epitope HER2 Peptide Vaccine TPIV100
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: permitted at physician's discretion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given ID
Study: NCT00673855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lubricant Eye Drops FID 112903
Description: Lubricant Eye Drops FID 112903 1 drop each eye 1 time

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optive Lubricant Eye Drops
Description: Optive Lubricant Eye Drops
Study: NCT03325309

Intervention type: OTHER
Intervention: Home-based cycling
Description: A single outpatient supervised session followed by a 3-month home-based cycling program tailored to patients' preferences
Study: NCT02072629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training of VHVs in iCCM
Description: Village Health Volunteers will be trained in Integrated Community Case Management (iCCM) of childhood illness
Study: NCT01740336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: GDC-0941 will be administered QD orally for 5 consecutive days each week.
Study: NCT04197687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given ID

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sargramostim
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: therapy are at the discretion of the treating physicians

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: at the discretion of the treating physicians.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Trastuzumab Emtansine
Description: at the discretion of the treating physicians.
Study: NCT03790423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 18F-ASIS
Description: Each patient will receive one injection of 18F-ASIS (approximately 200 Mbq)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET/CT scan
Description: Following one injection of 18F-ASIS the patients will be PET/CT scanned at 1 hour, 2 hours and 4 hours post-injection
Study: NCT01264081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 500 mg PO (orally) twice a day for 28 days (1 cycle). Up to 27 cycles allowed if response seen.
Study: NCT00134784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I]B-CIT SPECT imaging
Description: To assess \[123I\]B-CIT SPECT imaging